Sugi Predict

Sugi Predict / Compounds / SCHEMBL15970465

SCHEMBL15970465

SCHEMBL15970465

N#Cc1ccnc(SCc2ccccc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 3/20 0.53
▸ MAOB P27338 3/20 0.53
▸ ABL1 P00519 1/20 0.47
▸ RIN1 Q13671 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.46
▸ CTSB P07858 2/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ EGLN2 Q96KS0 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19944059 0.77 SQOR (0.37) MEN1KMT2AALDH1A1TDP1MAPK1
SCHEMBL4535380 0.77 KDM4E (0.37) HSD17B10MEN1KMT2ANPC1RAB9A
SCHEMBL31038332 0.76 MAOB (0.58) MAOAMAOBHSD17B10CTSBMEN1
SCHEMBL19859048 0.76 MAOB (0.58) MAOAMAOBHSD17B10CTSBMEN1
SCHEMBL1828420 0.76 HSD17B10 (0.50) ABL1RIN1HSD17B10MEN1KMT2A
SCHEMBL21906009 0.76 HSD17B10 (0.50) ABL1RIN1HSD17B10MEN1KMT2A
SCHEMBL21906037 0.76 HSD17B10 (0.50) ABL1RIN1HSD17B10CTSBMEN1
SCHEMBL21906129 0.76 HSD17B10 (0.50) MAOBABL1RIN1HSD17B10MEN1
SCHEMBL30665391 0.76 HSD17B10 (0.50) MAOBABL1RIN1HSD17B10MEN1
SCHEMBL29464847 0.76 HSD17B10 (0.50) ABL1RIN1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220235043-A1 SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS ACLARIS THERAPEUTICS, INC. 2022-07-28 — — US disclosed
US-20220235043-A1 SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS ACLARIS THERAPEUTICS, INC. 2022-07-28 — — US disclosed
US-10966980-B2 Pyrrolo[2,3-d]pyrimidine derivatives PFIZER INC. (US) 2021-04-06 — — US disclosed
WO-2021022178-A1 SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS ACLARIS THERAPEUTICS, INC. (US) 2021-02-04 — — WO disclosed
WO-2021022178-A1 SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS ACLARIS THERAPEUTICS, INC. (US) 2021-02-04 — — WO disclosed
EP-3180344-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE PFIZER (US) 2019-09-18 — — EP disclosed
EP-3290421-B1 COMBINATION OF PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES WITH ONE OR MORE ADDITIONAL AGENTS AS INHIBITORS OF JANUS- RELATED KINASES (JAK) PFIZER (US) 2019-01-02 — — EP disclosed
EP-3290421-A1 COMBINATION OF PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES WITH ONE OR MORE ADDITIONAL AGENTS AS INHIBITORS OF JANUS- RELATED KINASES (JAK) Pfizer Inc (US) 2018-03-07 — — EP disclosed
EP-2958921-B1 PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS KINASES (JAK) PFIZER (US) 2017-09-20 — — EP disclosed
EP-3180344-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE Pfizer Inc (US) 2017-06-21 — — EP disclosed
US-9549929-B2 Pyrrolo[2,3-D]pyrimidine derivatives PFIZER INC. (US) 2017-01-24 — — US disclosed
US-9545405-B2 Pyrrolo[2,3-D]pyrimidine derivatives PFIZER INC. (US) 2017-01-17 — — US disclosed
US-20160045508-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. (US) 2016-02-18 — — US disclosed
WO-2016024185-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE PFIZER INC. (US) 2016-02-18 — — WO disclosed
EP-2958921-A1 PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) Pfizer Inc. (US) 2015-12-30 — — EP disclosed
US-20150246048-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. 2015-09-03 — — US disclosed
US-20150225408-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. 2015-08-13 — — US disclosed
US-9035074-B2 Pyrrolo[2,3-D]pyrimidine derivatives PFIZER INC. (US) 2015-05-19 — — US disclosed
WO-2014128591-A1 PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) PFIZER INC. (US) 2014-08-28 — — WO disclosed
US-20140243312-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES PFIZER INC. (US) 2014-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225408-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 MAOA 3977/4885MAOB 3069/4885ABL1 59/4885
US-20220235043-A1 SUBSTITUTED SULFONAMIDE PYRROLOPYRIDINES AS JAK INHIBITORS JAK1, JAK3, JAK2 MAOA 3527/4885MAOB 3399/4885ABL1 143/4885
US-20160045508-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 MAOA 3832/4885MAOB 2610/4885ABL1 50/4885
US-10966980-B2 Pyrrolo[2,3-d]pyrimidine derivatives JAK3, JAK1, JAK2 MAOA 3832/4885MAOB 2610/4885ABL1 50/4885
US-20150246048-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 MAOA 3977/4885MAOB 3069/4885ABL1 59/4885
US-20140243312-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES JAK3, JAK1, JAK2 MAOA 3977/4885MAOB 3069/4885ABL1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.